The majority of targeted compounds, for example, EGFR, BRAF and MET inhibitors, as well as molecules directed towards rearranged kinases, are particularly effective when administered in the very beginning of the treatment of metastatic disease. This evidence concerns the gene EGFR and metastatic neoplasm.